Overview

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Status:
Completed
Trial end date:
2020-03-13
Target enrollment:
Participant gender:
Summary
A randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata
Phase:
Phase 2
Details
Lead Sponsor:
Concert Pharmaceuticals